- Home
- CANF vs ECPG Comparison
CANF vs ECPG Comparison
Compare CANF & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CANF | ECPG |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 1.2B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | CANF | ECPG |
|---|---|---|
| Price | $0.21 | $55.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.25 | ★ $59.50 |
| AVG Volume (30 Days) | ★ 10.2M | 230.5K |
| Earning Date | 02-03-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $560,000.00 | ★ $1,560,869,000.00 |
| Revenue This Year | $461.72 | $32.56 |
| Revenue Next Year | N/A | $3.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 17.52 |
| 52 Week Low | $0.17 | $26.45 |
| 52 Week High | $4.40 | $56.67 |
Technical Indicators
Market Signals| Indicator | CANF | ECPG |
|---|---|---|
| Relative Strength Index (RSI) | 39.03 | 62.42 |
| Support Level | $0.17 | $53.69 |
| Resistance Level | $0.27 | $56.00 |
| Average True Range (ATR) | 0.03 | 1.31 |
| MACD | -0.00 | -0.25 |
| Stochastic Oscillator | 33.63 | 69.12 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.